You are now leaving GSK Malta Health Portal

You are about to leave a GSK Website. By clicking this link, you will be taken to an external website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on this site. If you do not wish to leave this website, click on “Go Back” below:


Go back

Date of preparation: March 2018

Respiratory at GSK

Today, too many people are suffering unnecessarily because of the poor management of their asthma and chronic obstructive pulmonary disease (COPD). 1 While patients are benefiting from advances in the way respiratory disease is managed, more needs to be done to improve their health and quality of life.

Ellipta Critical Errors Study

Find out about the study and how Ellipta compares to commonly used asthma inhalers

Full results

Video player requires JavaScript enabled. You can download this video here:


  1. Vos et al. Global Burden of Disease Study 2013. The Lancet. 2015: 386(9995); 743-800

Trademarks are owned by or licensed to the GSK group of companies. ©2017 GSK group of companies or its licensor.